Arkolith/Insider Trading/JNCE/Form 4

Kamen Robert

DirectorJounce Therapeutics, Inc. (JNCE) · full profile →Form 4 · filed May 4, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
2 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 3, 2023Tender(U)61K——0
May 3, 2023Tender(U)34K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 3, 2023Disposed to issuer(D)20K——0
May 3, 2023Disposed to issuer(D)14K——0
May 3, 2023Disposed to issuer(D)16K——0
May 3, 2023Disposed to issuer(D)11K——0
May 3, 2023Disposed to issuer(D)16K——0
May 3, 2023Disposed to issuer(D)16K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001640455-23-000110) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML